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Even though hyperthermia is a promising treatment
for cancer, the relationship between specific temper-
atures and clinical benefits and predictors of sensi-
tivity of cancer to hyperthermia is poorly understood.
Ovarian and uterine tumors have diverse hyperther-
mia sensitivities. Integrative analyses of the specific
gene signatures and the differences in response
to hyperthermia between hyperthermia-sensitive
and -resistant cancer cells identified CTGF as a key
regulator of sensitivity. CTGF silencing sensitized
resistant cells to hyperthermia. CTGF small inter-
fering RNA (siRNA) treatment also sensitized resis-
tant cancers to localized hyperthermia induced by
copper sulfide nanoparticles and near-infrared laser
in orthotopic ovarian cancer models. CTGF silencing
aggravated energy stress induced by hyperthermia
and enhanced apoptosis of hyperthermia-resistant
cancers.INTRODUCTION
Therapeutic hyperthermia is based on the premise of raising the
temperature of tumor tissue to 40C–43C. It has been used for
treatment of ovarian and other cancers. The rationale for this
therapy is based on the direct-killing effects of temperatures
above 41C–42C (Wust et al., 2002). Hyperthermia also isCell Repo
This is an open access article under the CC BY-Napplied as an adjunctive therapy with various established cancer
treatments, such as radiotherapy and chemotherapy (Moyer and
Delman, 2008; Nagata et al., 1997; Palazzi et al., 2010; Lim et al.,
2015). Some studies have suggested that hyperthermia acti-
vates the immune system against tumor cells, by increasing
the release of heat shock proteins (HSPs) associated with tu-
mor-specific antigens from heat-stressed or dying tumor cells
that are phagocytized by antigen-presenting cells (APCs) (Binder
et al., 2000).
As interest in hyperthermic treatment of cancer has increased,
significant progress has been made in developing strategies to
heat tumors via local, regional, and whole-body hyperthermia
(van der Zee, 2002). Different types of energy have been used,
including microwaves and radio waves (Gazelle et al., 2000;
Seki et al., 1999), magnetic heating (Lee et al., 2011; Rodrı´-
guez-Luccioni et al., 2011), and ultrasound (Jolesz and Hynynen,
2002). Regional hyperthermia (e.g., hyperthermic intraperitoneal
chemotherapy [HIPEC] heated to 42C) theoretically enables
direct contact between tumor cells and the chemotherapeutic
agent to control residual microscopic disease (Wademan et al.,
2012).
Even though hyperthermia is a promising therapeutic
approach, multiple obstacles remain to be cleared. One of the
major issues is that the tumor temperatures that must be
reached for obtaining clinical efficacy are largely undefined
(Wust et al., 2002). In the present study, we carried out a series
of experiments to determine themolecular mechanisms of tumor
response to hyperthermia. Moreover, we utilized nanoparticle
(NP)-based approaches to silence key pathways to enhance
tumor response to hyperthermia.rts 17, 1621–1631, November 1, 2016 ª 2016 The Author(s). 1621
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Variability in Hyperthermia Sensitivity of Ovarian and Uterine Cancer Cell Lines
(A) Ovarian and uterine cancer cells were treated with hyperthermia for 1 hr at the indicated temperatures and then incubated at 37C. Cell viability was
determined using an MTT assay at 24 hr. The value in each graph represents the LT50 that produced 50% cell death. Average, ± SEM; n = 3–6.
(B) Difference in each LT50 from the median LT50 (46.5C) in the tested cells. The cells having LT50s above or below the median LT50 were classified as HTR or
HTS, respectively.
See also Figures S1 and S2.RESULTS
Diversity of Hyperthermia Sensitivity in Ovarian and
Uterine Cancer Cell Lines
We first monitored the temperature transition in tumors during
HIPEC in high-grade serous ovarian cancer patients (Figure S1;
Table S1). Even though the perfusion temperature at the
entrance was maintained at 42.5C, the temperature in most of
the tumors was about 40C and the potential clinical benefit of
these lower temperatures is unclear. We sought to determine
the temperatures at which various cancer cells lose viability
and to identify potential molecular regulators of sensitivity to hy-
perthermia. To address these questions, we tested hyperthermia
sensitivity in a range of ovarian (A2780, A2780CP20, SKOV3,
ES2, HeyA8, and PEO4) and uterine (Hec-1A, SKUT-2, KLE,
and ISHIKAWA) cancer cells. We treated each cell line with hy-
perthermia for 1 hr, equivalent to the duration of HIPEC, using1622 Cell Reports 17, 1621–1631, November 1, 2016an incubator at the indicated temperatures, and we assessed
cell viability (Figure 1A). We defined the temperature that pro-
duced 50% cell death as the median lethal temperature 50
(LT50) using curve fitting.
Based on the calculation of LT50s, the difference between the
lowest and highest LT50 was about 4C, suggesting that the
cells showed substantial variability in sensitivity to hyperthermia.
The median LT50 in the tested cells was 46.5C. We classified
cells with LT50s above the median, SKOV3, HeyA8, ES2,
PEO4, and KLE, as hyperthermia-resistant (HTR) cells. We clas-
sified cells with LT50s below the median, A2780, A2780CP20,
Hec-1A, ISHIKAWA, and SKUT-2, as hyperthermia-sensitive
(HTS) cells (Figure 1B). Since hyperthermia can increase blood
flow, we also examined whether endothelial cells are affected
by hyperthermia. For these experiments, we used RF24 endo-
thelial cells (Pecot et al., 2013). The LT50 of RF24 cells was
45.5C; thus, these cells were classified as HTS cells
Figure 2. Specific Gene Signatures in HTR Cells
(A) Volcano plot of upregulated and downregulated genes in HTR cells compared with those in HTS cells from the CCLE database. The fold change in gene
expression and p values for HTR cells versus HTS cells are represented in the horizontal and vertical axes, respectively. Filtering according to a fold change
greater than 2 and a p value less than 0.05 identified 327 upregulated and 92 downregulated genes.
(B) Heatmaps show the expression of the top 30 upregulated and downregulated genes in HTR cells.
(C) Network map of the top 30 upregulated and downregulated genes created using IPA. Red and green indicate upregulation and downregulation, respectively,
with darker shades indicating greater changes in expression. The lines indicate binding of two gene products, and lines terminating with arrows indicate one gene
product acting on another gene product.
See also Figure S3.(Figure S2A). Hyperthermia treatment also enhanced sensitivity
of HTS A2780 and HTR HeyA8 cells to cisplatin (Figure S2B).
Specific Gene Signatures in HTR Cells as Determined
Using Comprehensive Gene Expression Analysis
To identify potential molecular regulators of sensitivity of cancer
cells to hyperthermia, we compared the gene expression profiles
for HTS and HTR cells using the Cancer Cell Line Encyclopedia
(CCLE) database. Specifically, we compared the gene expres-
sion profiles of HTS (A2780, ISHIKAWA, and Hec-1A) and HTR
(SKOV3, HeyA8, ES2, and KLE) cell lines. We identified differen-
tially expressed genes between HTS and HTR lines setting the
cutoff at p value < 0.05 and fold change > 2. This identified
327 upregulated genes and 92 downregulated genes in HTR
cells (Figure 2A; Table S2). Heatmaps of the expression of the
top 30 upregulated and downregulated genes in HTR cells are
shown in Figure 2B. Enriched gene ontology (GO) annotations
for biological processes for these top 30 genes were related to
wound healing, cell motion, and cell adhesion (Figure S3A). We
then examined these 30 genes using ingenuity pathway analysis
(IPA) to identify molecules that can possibly interact with each
other in HTR cells. We found that 15 genes were potentially con-
nected with each other in HTR cells (Figure 2C). We further
analyzed the expression of the 15 genes in ten cell lines using
qRT-PCR (Figure S3B). The baseline expression of these geneswas generally correlated with increased gene expression in HTR
cells in the CCLE database. Among the 15 genes, the expression
of FN1, CXCL1, and IL8 was highly increased in HTR compared
with HTS cells.
Determination of the Difference in Response of Ovarian
Cancer Cells to Hyperthermia Using Quantitative
Proteomics
To examine the mechanisms by which HTR cells survive under
hyperthermia, we first compared global changes in gene expres-
sion between HTS A2780 and HTR SKOV3 cells after hyperther-
mia using gene microarrays. Most genes that were significantly
upregulated after hyperthermia were common between A2780
and SKOV3 cells (Figures S3C and S3D; Table S3). These results
suggested that hyperthermia sensitivity was either not depen-
dent on changes in gene expression or that there are changes
in protein abundance in response to hyperthermia.
To test this hypothesis, we subjected A2780 and SKOV3 cells
treated with hyperthermia to isobaric tandem mass tags (TMT)
labeling and offline two-dimensional liquid chromatography-tan-
dem mass spectrometry (2D-LC-MS/MS) to comprehensively
assess changes in protein expression induced by hyperthermia.
We treated the cells with hyperthermia at 46C for 1 hr and har-
vested protein after incubation at 37C for 4 hr. We identified 53
upregulated and 159 downregulated proteins in A2780 cells, andCell Reports 17, 1621–1631, November 1, 2016 1623
Figure 3. Determination of the Difference in Response to Hyperthermia in A2780 and SKOV3 Cells Using Quantitative Proteomics
(A) Volcano plots of differentially expressed proteins in HTS A2780 (left) and HTR SKOV3 (right) cells after hyperthermia identified using 2D-LC-MS/MSwith TMT.
Upregulated and downregulated proteins (fold change, > 0.5; p < 0.2 for A2780 and p < 0.05 for SKOV3) are highlighted in red and green, respectively.
(B) Graphs show the top ten enriched GO annotations for biological processes for differentially expressed proteins in A2780 (upper) and SKOV3 (lower) cells.
(C) Graph shows the top ten canonical pathways in SKOV3 cells in response to hyperthermia as determined using IPA.
(D) Left: schematic of the glycolysis pathway. Enzymes highlighted in green represent downregulated proteins in SKOV3 cells after hyperthermia. Right: heatmap
shows differential expression patterns for proteins involved in the glycolysis pathway according to proteomic analysis.
(legend continued on next page)
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we identified 309 upregulated and 536 downregulated proteins
in SKOV3 cells (Figure 3A; Table S4). We analyzed the GO terms
for biological processes for the differentially expressed proteins
in A2780 and SKOV3 cells using the Database for Annotation,
Visualization and Integrated Discovery (DAVID), and we found
that processes involved in glucose metabolism were specifically
enriched in SKOV3 cells after hyperthermia (Figure 3B). We also
found that glycolysis was the primary pathway affected by hy-
perthermia in SKOV3 cells according to canonical pathway anal-
ysis (Figure 3C). Expression of most of the proteins involved in
the glycolysis pathway was downregulated in SKOV3 cells, sug-
gesting that the glycolysis pathway was impaired after hyper-
thermia treatment (Figure 3D). Upon examining the interactions
between the 15 molecules that are differentially expressed be-
tween HTS and HTR cells and the glycolysis-related molecules
identified in the proteomics described here, we identified FN1,
SGK1, CTGF, and CXCL1 to be the potential players regulating
the glycolysis pathway in HTR cells (Figure 3E).
Genes Responsible for Hyperthermia Resistance in
Ovarian Cancer Cells
According to network mapping, FN1, SGK1, CTGF, and CXCL1
were likely linked with glycolysis (Figure 3E). Because CXCL1
was likely downstream of the glycolysis pathway, we focused
our effort on FN1, SGK1, and CTGF. We measured FN1,
SGK1, and CTGF protein expression in ten cell lines via western
blotting (Figures 4A and S4A). The expression was increased in
HTR cells, which was generally consistent with the FN1, SGK1,
and CTGF gene expression profiles of the ten cell lines
(Figure S3B).
We then examined the potential effects of silencing CTGF,
FN1, or SGK1 on response to hyperthermia in HTR (SKOV3,
HeyA8, ES2, and KLE) and HTS (A2780) cells using small inter-
fering RNA (siRNA) (Figure 4B). Silencing of FN1 and SGK1 did
not sensitize HTR or HTS cells to hyperthermia (Figures S4B–
S4E). On the other hand, silencing of CTGF sensitized the HTR
cells to hyperthermia with a decrease in the LT50 by 1.0C–
2.5C (Figure 4C). Downregulation of CTGF expression had no
effect on sensitization to hyperthermia in A2780 cells. No sensi-
tization was observed when HTS RF24 endothelial cells were
treated with siCTGF (Figures S2C and S2D). Transfection of a
CTGF-expressing vector enhanced CTGF mRNA levels in
HeyA8 cells, which made the cells tolerant of hyperthermia
with about a 2C increase in the LT50 (Figures 4D and 4E).
Because CTGF is a secreted molecule, we treated HTR cells
with recombinant human CTGF (rCTGF) in a medium to examine
its functional effect. HTRHeyA8 and ES2 cells treated with CTGF
siRNA (siCTGF) exhibited tolerance of hyperthermia with LT50
increases of 2.3C and 1.0C following the addition of rCTGF
(Figure 4F). Conversely, anti-CTGF antibody treatment sensi-
tized SKOV3 cells to hyperthermia (Figure S2E).(E) Network map of 15 upregulated and downregulated genes in HTR cells that w
identified in SKOV3 cells using 2D-LC-MS/MS with TMT. Red and green indicate
greater changes in expression. The lines indicate binding of two gene products,
gene product.
See also Figure S3.Sensitization of Tumors to Hyperthermia by CTGF
Silencing In Vivo
Next, we evaluated the effect of CTGF silencing on sensitization
to hyperthermia and tumor growth in orthotopic models of
ovarian cancer. First, in the HeyA8 model, we administered
siCTGF into the peritoneal cavity twice weekly using the 1,2-dio-
leoyl-sn-glycero-3-phosphatidylcholine (DOPC) nanoliposomal
delivery platform (Figure 5A). This resulted in decreased CTGF
expression in tumors (Figures S5A). The day before near-infrared
(NIR) laser treatment, we intravenously injected CuS NPs modi-
fied with poly(ethylene glycol) (PEG-CuS NPs) into tumor-
bearing mice (day 18). PEG-CuS NPs about 10 nm in diameter
(Figures S5D andS5E) circulate in the blood for long periods after
systemic administration, and they passively accumulate in tu-
mors via an enhanced permeability and retention (EPR) effect
(Zhou et al., 2010; Hatakeyama et al., 2011). We then treated tu-
mors with local hyperthermia using an NIR laser at 980 nm for
5 min on day 19, because CuS NPs can convert the optical en-
ergy of an NIR laser to thermal energy (Figure S5F) (Zhou et al.,
2015). As temperatures of 46C–60C are associated with
reversible cellular damage in proportion to the exposure time
(Vanagas et al., 2010; Wood et al., 2002), we maintained the tu-
mor temperature at about 50C (Figure 5B).
We harvested HeyA8 tumors on day 30, and we found that
local hyperthermia decreased tumor weights and nodule
numbers in control siRNA (siCont)- and siCTGF-treated mice
(Figures 5C–5F). Furthermore, tumor growth and metastasis
were markedly suppressed by the combination of CTGF
silencing and local hyperthermia, with no changes in body
weight (Figures 5 and S5B). A significant increase in cleaved cas-
pase-3-positive cells was observed after hyperthermic treat-
ment in HeyA8 tumors treated with siCTGF (Figure 5G). No
obvious decrease in the number of Ki67-positive tumor cells
was observed in the siCTGF plus hyperthermia treatment group
compared to the siCont group (Figure S5C). Next, we used the
HTR SKOV3 tumors surgically implanted into the ovary of nude
mice (n = 9–10 per group). The tumor weight and metastasis
were significantly decreased by the combination of CTGF
silencing and local hyperthermia (Figures 5H–5K). These results
demonstrated that CTGF silencing in vivo sensitized ovarian
tumors to local hyperthermia treatment.
Identification of the Mechanism by which CTGF Causes
Hyperthermia Resistance
To further examine how CTGF silencing sensitized HTR cells to
hyperthermia, we examined CTGF levels in HeyA8 and SKOV3
cells longitudinally. Since the expression of some housekeeping
genes might be affected by hyperthermia, we confirmed that
b-actin and 18S could be used as reference genes in a hyper-
thermia experiment (Figures S6A–S6C). CTGF expression
increased after hyperthermic treatment, and the increase ofere identified in the CCLE database and glycolysis-involved proteins that were
upregulation and downregulation, respectively, with darker shades indicating
and lines terminating with arrows indicate one gene product acting on another
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Figure 4. The Effect of CTGF Silencing on Sensitization of Cancer Cells to Hyperthermia In Vitro
(A) Immunoblot shows CTGF expression in tested ovarian and uterine cancer cell lines.
(B) Graphs of the silencing of CTGF in tested cell lines by siRNA. Cells were transfected with siRNA at 40 nM. mRNA expression levels in the cells were evaluated
48 hr after transfection using qRT-PCR. Average, ± SEM; n = 3.
(C) The effect of silencing of CTGF gene on sensitization of the cells to hyperthermia. Cells treated with siRNA for 48 hr were treated with hyperthermia at
the indicated temperatures for 1 hr. Cells were further incubated at 37C, and their viability was determined using an MTT assay 24 hr after the initiation of
hyperthermia. LT50s were calculated using a dataset at least three times. Average, ± SEM; n = 3–8.
(D) Time profile shows CTGF mRNA expression in HeyA8 cells treated with CTGF-expressing vector, as determined using qRT-PCR. Average, ± SEM; n = 3.
(E) The effect of CTGF expression on the sensitization of cells to hyperthermia. HeyA8 cells that were treated with CTGF-expressing vector or a control vector for
48 hr were subjected to hyperthermia at the indicated temperature for 1 hr. Cell viability was determined 24 hr after the beginning of hyperthermic treatment.
Average, ± SEM; n = 3.
(F) The effect of recombinant CTGF (rCTGF) treatment on hyperthermia sensitivity. HeyA8 and ES2 cells were treated with rCTGF (200 ng/ml) 3 hr after the
beginning of hyperthermic treatment. Cell viability was determined at 24 hr after the initiation of hyperthermia. Average, ± SEM; n = 3.
See also Figures S2 and S4.CTGF after hyperthermia was suppressed by siCTGF-based
treatment (Figure 6A). CTGF protein expression also increased
after hyperthermic treatment in HeyA8 cells, but the increase
was blocked by siCTGF-based treatment over 24 hr (Figure 6B).
Silencing of CTGF increased the population of sub-G0/G1
(apoptotic) cells at 24 hr after hyperthermia (Figure 6C), and
it induced cell death at 24 hr after hyperthermia treatment
(Figure 6D).
As shown in Figure 3D, quantitative proteomic analysis sug-
gested that glycolysis was impaired in the HTR SKOV3 cells after
hyperthermia treatment. Inhibition of glycolysis results in energy
stress. AMP-activated protein kinase (AMPK) plays a key role in
regulating cellular energy homeostasis under energy stress.
AMPK is activated by phosphorylation when energy stress oc-
curs (Hardie et al., 2012). We observed increased phosphory-1626 Cell Reports 17, 1621–1631, November 1, 2016lated AMPK levels induced by hyperthermia, and these levels
were enhanced in HeyA8 and SKOV3 cells treated with siCTGF
(Figure 6E). The increase was independent of LKB1 activity (Fig-
ure S6D).The sensitization to hyperthermia also was observed
when SKOV3 cells were treated with metformin (Figure S2F),
which can activate AMPK phosphorylation and induce energy
stress (Lengyel et al., 2015). It is possible that CTGF regulates
glycolytic activity by modulating the expression of glycolysis-
related genes after hyperthermia. To confirm that inhibition of
the glycolysis pathway affected sensitivity of HTR cells to hyper-
thermia, we treated HeyA8 and SKOV3 cells with a glycolysis in-
hibitor, 2-deoxy-D-glucose (2-DG). This treatment sensitized
HTR HeyA8 and SKOV3 cells to hyperthermia with a decrease
in the LT50 by about 2C (Figure 6F), and it increased the popu-
lation of sub-G0/G1 in HeyA8 and SKOV3 cells (Figure 6G).
Figure 5. CTGF Silencing-Induced Sensitization of HeyA8 Tumors to Hyperthermia by Local Thermal Ablation with CuSNPs and an NIR Laser
In Vivo
(A) Our animal experiment schedule. Mice were injected intraperitoneally with luciferase-transfected HeyA8 cells or injected into the ovary with luciferase-
transfected SKOV3. SiRNA/DOPC liposomes (5 mg siRNA/mouse) were administered via intraperitoneal injection twice weekly beginning on day 7 after cell
injection. On day 18, CuS NPs (8 OD/mouse) were injected intravenously into the mice, and, on day 19, tumors were treated with an NIR laser for 5 min. Tumors
were collected from the mice on day 30 for the HeyA8 model or day 40 for the SKOV3 model.
(B) Representative transition of the temperature of an HeyA8 tumor. The temperature was monitored during local hyperthermic treatment using a thermal camera
(red line) and fiber probe (black line).
(C–E) Average tumor weights (C), numbers of tumor nodules (D), and numbers of distant metastatic nodules (E) of HeyA8 model on day 30 are shown (n = 4–5/
group). Average, ± SEM.
(F) Representative pictures show HeyA8 tumor burdens in mice (arrows).
(legend continued on next page)
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DISCUSSION
Here we identified molecular determinants of cancer cell sensi-
tivity to hyperthermia. We characterized the role of CTGF as a
key target for enhancing response to hyperthermia treatment.
CTGF silencing inhibited the recovery of glycolytic activity after
hyperthermia, which resulted in energy stress-induced cell death
(Figure 7).
The temperatures used in clinical hyperthermia treatment
range from 40C to 45C; typically, the temperature is 42.5C
in cases of regional hyperthermia, such as during HIPEC (Wade-
man et al., 2012). However, most of the prior studies lacked any
actual assessment of temperature in tumors. Moreover, given
the gradient between the temperature of infusate and actual tu-
mor-level temperatures, true hyperthermia is unlikely to have
been achieved in such treatments. The clinical benefit of such
a low temperature for cancer therapy is unclear. We discovered
that cancer cells exhibited substantial diversity in their sensitivity
to hyperthermia as determined by the LT50.
We observed little difference in gene expression changes after
hyperthermia between HTS versus HTR cells despite substantial
difference in protein expression. It is known that heat shock
response where heat shock proteins are upregulated rapidly is
highly conserved in all organisms for the protection of cells
from a wide range of harmful conditions, including heat shock
(Jolly andMorimoto, 2000), which is consistent with our observa-
tion that enhanced gene expression induced by hyperthermic
treatment occurred independently of hyperthermia sensitivity.
While RNA molecules are typically only damaged above 85C–
90C, thermal stability of protein represents a wide range (Bis-
chof and He, 2005). These may account for wider effects on
expression of protein than RNA by hyperthermia.
Our findings related to the role of CTGF in glycolysis-related
genes are supported by its role in development (de Winter
et al., 2008). For example, downregulation of glycolysis-related
genes, such as Pgm1, Pgam1, and Eno1, and the decrease in
glycolytic activity and ATP levels have been reported in chondro-
cytes from Ctgf (Ccn2)-null mice (Maeda-Uematsu et al., 2014;
Murase et al., 2016). It is likely that CTGF regulates the expres-
sion of glycolysis-related genes after hyperthermia to prevent
cancer cells from energy-stressed cell death. However, some
studies have reported that energy stress downregulates the
expression of CTGF via the inactivation of YAP in the Hippo
pathway in HEK293 cells (Mo et al., 2015; Wang et al., 2015). It
is possible that such signaling may be context dependent, since
the 14-3-3 signaling pathway was downregulated in the HTR
SKOV3 cells after hyperthermia (Figures 3C and S3E).
To overcome the challenges with fluid-based hyperthermia,
we used local thermal ablation with CuS NPs and an NIR laser.
CuS NPs have smaller size than plasmonic gold-based nano-(G) Immunohistochemistry assay of cleaved caspase-3 in tumor sections (scal
in HeyA8 tumors. Right: bar graph represents ratio of cleaved caspase-3-pos
Average, ± SEM.
(H–J) Average tumor weights (H), numbers of tumor nodules (I), and frequency of
group). Average, ± SEM.
(K) Representative pictures show SKOV3 tumor burdens in mice (arrows).
See also Figure S5.
1628 Cell Reports 17, 1621–1631, November 1, 2016structures, which give them better chances to extravasate into
extravascular fluid space. In addition, the absorption properties
of CuS NPs are not subject to change upon repetitive laser irra-
diation. Our approach for gene silencing with a DOPC nanolipo-
somal delivery system can be readily translated into clinical set-
tings (Rupaimoole et al., 2014; Wu et al., 2014) to sensitize
cancers to hyperthermia, and it can be used for other key targets.
Such an approach also could be beneficial for cancer cells only
exposed to sub-lethal thermal stress by HIPEC.
The tumor endothelial cell is also an important target for hyper-
thermia. Based on the LT50 of RF24 cells, endothelial cells were
sensitive to hyperthermia. Thus, while our study focuses on the
effect of hyperthermic treatment on tumor cells, it is possible
that the decreases in tumor burden after hyperthermia treatment
in vivo were due to the effects of both tumor and endothelial
compartments.
In summary, we discovered that cancer cells have diverse hy-
perthermia sensitivity. CTGF is an important regulator of hyper-
thermia sensitivity, and it may represent an important target for
further development.
EXPERIMENTAL PROCEDURES
Our materials; HIPEC procedure; cell culture; the cell-cycle study; immuno-
blotting; RNA extraction; qRT-PCR; TMT labeling and 2D-LC-MS/MS-based
quantitative proteomics; cDNA microarray analysis, synthesis, and transmis-
sion electron microscopy (TEM) of CuS NPs; and immunohistochemistry are
described in the Supplemental Experimental Procedures. 12 patients were
enrolled in the study following IRB approval.
Hyperthermic Treatment of Cancer Cells In Vitro
The details are described in the Supplemental Experimental Procedures.
Briefly, cells were treated with hyperthermia via heating cells in an incubator
for 1 hr at the indicated temperatures followed by incubation at 37C in a
regular cell culture incubator. At the indicated time points, viability was
determined by 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bro-
mide (MTT) assay. The LT50 that produced 50% cell death was calculated via
curve fitting. Transfection of siRNA or pDNA and treatment procedures are
described in the Supplemental Experimental Procedures.
CCLE Database Analysis
The expression data for HTR cells (SKOV3, HeyA8, ES2, and KLE) and HTS
cells (A2780, Hec-1A, and ISHIKAWA) were downloaded from the CCLE web-
site (https://portals.broadinstitute.org/ccle/home). The details are available in
the Supplemental Experimental Procedures.
DOPC Liposome Preparation
DOPC liposomes encapsulating siRNAwere prepared as described previously
(Rupaimoole et al., 2014; Wu et al., 2014).
Synthesis of CuS NPs
CuSNPswere synthesized according to previously reported procedures (Zhou
et al., 2010, 2015). The details are available in the Supplemental Experimental
Procedures.e bar, 50 mm). Left: representative images show cleaved caspase-3 staining
itive cells per total cells per hours post fertilization (hpf, n = 13–18 fields).
metastases to distant sites (J) of SKOV3 model on day 40 are shown (n = 9–10/
Figure 6. Mechanism by which CTGF Regulates Hyperthermia Resistance
(A) Time profile ofCTGFmRNA expression in HeyA8 and SKOV3 cells treated with control siRNA (siCont) or siCTGF, as determined using qRT-PCR. Cells treated
with siCont of siCTGF were treated with hyperthermia at 46C for 1 hr (0–1 hr) and further incubated at 37C up to the time points. Average, ± SEM; n = 3.
(B) Time profile of CTGF protein expression in HeyA8 cells treated with siCont or siCTGF. Left: immunoblot shows CTGF and b-actin expression. Right: band
intensity of CTGF and b-actin was semiquantified using the ImageJ software program (NIH). Average, ± SEM; n = 3.
(C) Sub-G0/G1 (apoptotic) populations of HeyA8 and SKOV3 cells treated with siCont or siCTGF after hyperthermia at the indicated time points are shown.
Average, ± SEM; n = 3.
(D) Interference contrast images show HeyA8 and SKOV3 cells treated with siCont or siCTGF after hyperthermia. Scale bars, 100 mm.
(E) Time profiles of phosphorylated AMPK (pAMPK) and AMPK expression in HeyA8 and SKOV3 cells treated with siCont or siCTGF. Left: immunoblot shows
pAMPK and total AMPK expression. Right: band intensity of pAMPK and AMPK was semiquantified using the ImageJ software program. Average, ± SEM; n = 3.
(F) The effect of inhibition of glycolytic activity on the sensitivity of HTR HeyA8 and SKOV3 cells to hyperthermia. HeyA8 and SKOV3 cells treated with 2-DG
(25 mM) were treated with hyperthermia at the indicated temperatures, and viability was determined at 24 hr after the initiation of hyperthermia. Average, ± SEM;
n = 3.
(G) Sub-G0/G1 populations of HeyA8 and SKOV3 cells treated with 2-DG (25 mM) were determined 24 hr after hyperthermic treatment at the indicated
temperatures. Average, ± SEM; n = 3.
See also Figures S2 and S6.
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Figure 7. A Proposed Mechanism of CTGF-Mediated Hyperthermia
Resistance
Hyperthermia inhibits glycolytic activity. On the other hand, CTGF is upregu-
lated after hyperthermia. Upregulated CTGF may regulate glycolytic activity,
which prevents HTR cells from undergoing energy stress and death. Silencing
of CTGF presumably inhibits the activation of glycolytic activity in HTR cells
after hyperthermia, and it induces energy stress and cell death.In Vivo Models
Orthotopic mouse models of ovarian cancer were developed as described
previously (Rupaimoole et al., 2014; Wu et al., 2014), and the details are avail-
able in the Supplemental Experimental Procedures. SiRNA-incorporated
neutral DOPC nanoliposomes were injected intraperitoneally at a dose of
5 mg siRNA/mouse twice weekly for about 3 weeks beginning 1 week after
cell injection. Photothermial ablation using CuS NPs and an NIR laser was
used for in vivo local hyperthermic treatment. The details are described in
the Supplemental Experimental Procedures.
Protein Expression Analysis Using TMT Labeling and
2D-LC-MS/MS-Based Quantitative Proteomics
The details of proteomic sample preparation, LC-MS/MS analysis, and prote-
omic data analysis are available in the Supplemental Experimental Proced-
ures. All raw files were deposited to the ProteomeXchange Consortium via
the PRIDE partner repository with the dataset identifier PRIDE: PXD005055
and 10.6019/PXD005055.
ACCESSION NUMBERS
The accession numbers for the raw files reported in this paper are PRIDE:
PXD005055 and 10.6019/PXD005055.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and four tables and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.10.020.
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